A synthetic peptide for use as a blocking control in assays to test for specificity of SLAMF6 antibody, Alternative Names: SLAMF6 control peptide, SLAMF6 antibody Blocking Peptide, Anti-SLAMF6 Blocking Peptide, Slam Family Member 6 Blocking Peptide, KALI Blocking Peptide, KALIb Blocking Peptide, Ly108 Blocking Peptide, MGC104953 Blocking Peptide, NTB-A Blocking Peptide, NTBA Blocking Peptide, SF2000 Blocking Peptide, SLAMF6, SLAMF-6, SLAMF 6, SLAMF-6 Blocking Peptide, SLAMF 6 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
SLAMF6
(SLAM Family Member 6 (SLAMF6))
Hintergrund
SLAMF6 is a type I transmembrane protein, belonging to the CD2 subfamily of the immunoglobulin superfamily. SLAMF6 is expressed on Natural killer (NK), T, and B lymphocytes. It undergoes tyrosine phosphorylation and associates with the Src homology 2 domain-containing protein (SH2D1A) as well as with SH2 domain-containing phosphatases (SHPs). It may function as a coreceptor in the process of NK cell activation. It can also mediate inhibitory signals in NK cells from X-linked lymphoproliferative patients.